Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical evidence of parenteral nutrition associated cholestasis~* Direct bilirubin greater or equal to 2 mg/dL on 2 consecutive measurements~* Expected parenteral nutrition course greater than 30 days~* Acquired or congenital gastrointestinal disease~* \> 2 weeks of age and \< 18 years of age~* \> 60% calories from parenteral nutrition~* Failed standard therapies to prevent progression of liver disease (Actigal, cyclic parenteral nutrition, avoidance of overfeeding, reduction/removal of copper from parenteral nutrition if elevated my laboratory analysis, advancement of enteral feeds)~Exclusion Criteria:~* Inborn errors of metabolism~* Extracorporeal Membrane Oxygenation~* Seafood, egg, or Omegaven allergy~* Documented case of liver disease other than Parenteral Nutrition Associated Cholestasis~* Hemorrhagic disorder~* Anticoagulant therapy~* Hemodynamically unstable or in shock~* Comatose state~* Stroke, pulmonary embolism, recent myocardial infarction~* Diabetes~* Fatal chromosomal disorder~* Enrollment in any other clinical trial involving an investigational agent~* Patient, parent, or legal guardians unable or unwilling to give consent~* Patient expected to be weaned from parenteral nutrition in 30 days~* unable to tolerate necessary monitoring~* Patient requiring aspirin or toradel or motrin~* Patient requiring dialysis

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Omegaven (Type: EXPERIMENTAL): 0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).